Recursion Pharmaceuticals Inc (RXRX) USD0.00001 A

Sell:$5.73Buy:$5.75$0.06 (0.96%)

NASDAQ:1.26%
Market closed | Prices delayed by at least 15 minutes
Sell:$5.73
Buy:$5.75
Change:$0.06 (0.96%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$5.73
Buy:$5.75
Change:$0.06 (0.96%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Recursion Pharmaceuticals, Inc. is a clinical stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology include REC-617, REC-1245, REC-3565 and REC-4539. Its clinical programs in rare diseases include REC-994, REC-4881, REC-2282, and REC-3964. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors.

Key people

Christopher Gibson
President, Chief Executive Officer, Director
Ben R. Taylor
Chief Financial Officer
Kristen Rushton
Chief Operating Officer
Lina Nilsson
Senior Vice President - Head of Platform
David Hallet
Chief Scientific Officer
Najat Khan
Director, Chief Research and Development Officer, Chief Commercial Officer
Matthew Kinn
Chief Business Officer
David J. Mauro
Chief Medical Officer
Robert M. Hershberg
Independent Chairman of the Board
Namandje N. Bumpus
Director
Franziska Michor
Director
Elaine D. Sun
Director
Zachary Bogue
Independent Director
Click to see more

Key facts

  • EPIC
    RXRX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US75629V1044
  • Market cap
    $2.24bn
  • Employees
    840
  • Shares in issue
    395.07m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.